APA (7th ed.) Citation

Gallant, J., Altice, F., & Folse, H. (2016). PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES. Value in Health, 19(3), A214. https://doi.org/10.1016/j.jval.2016.03.1206

Chicago Style (17th ed.) Citation

Gallant, J., F. Altice, and H.J Folse. "PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES." Value in Health 19, no. 3 (2016): A214. https://doi.org/10.1016/j.jval.2016.03.1206.

MLA (9th ed.) Citation

Gallant, J., et al. "PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES." Value in Health, vol. 19, no. 3, 2016, p. A214, https://doi.org/10.1016/j.jval.2016.03.1206.